pharmaphorum January 14, 2026
Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement its current activities in patient-facing, generative AI (GenAI) agents.
Palo Alto, California-based Hippocratic AI said it has also appointed Dr Ahad Wahid as president of a newly-formed life sciences division and formed an executive advisory panel to guide that side of the business.
Hippocratic AI was set up in 2023 to develop GenAI agents for a range of healthcare applications, from booking appointments to healthcare billing, in partnership with several healthcare systems in the US. Its core mission was to develop a safety-focused large language model (LLM) for healthcare, primarily to address healthcare worker shortages by handling non-diagnostic,...
Today's Sponsors
Today's Sponsor